CanaQuest Announces Key Appointments to Team to Drive CQ-001 through Clinical Trials

CanaQuest Medical Corp (“CanaQuest” or the “Company”) (OTC: CANQF), is pleased to announce strategic additions to its executive team with expertise in conducting clinical trials and US FDA drug approval success. The team plans to effectively navigate the regulatory approval process for Drug Candidate, CQ-001 (cannabidiol + proprietary API composition), to treat rare neurological conditions with a primary focus on epilepsy. Furthermore, a nutraceutical version of the formulation, Mentanine^™, is scheduled for clinical studies to investigate its potential applications across various indications, paving the way for future clinical trials.